Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Guidelines
Haematology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline

2026National

United States

Read the PDF Original at the sourceAsk Osler about this guideline

On this page

Read the guideline
Abstract
Source and rights

Read the guideline

Full guideline, as published937 KBOpen in a new tab Download

Abstract

To provide updated guidance regarding the therapy for multiple myeloma.

ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.

The updated review identified a total of 161 relevant randomized trials.

More in haematology

Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026Added 23 Jul 2026PDF
Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026Added 31 Jul 2026PodcastInfographic

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.

Source and rights

Published by Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The PDF is shown as published and remains the work of its authors and publisher; the original is at the source linked here. Rights holders can ask us to remove a file at info@prognia.nl.

ascopubs.org/doi/10.1200/JCO-25-02587?url_ver=Z39.88-2003&rfr_id=ori:rid:crossre

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Published: 2026
Applies to: 🇺🇸 United States
Scope: National
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DOI: 10.1200/JCO-25-02587
PubMed: 41494138
Added to Prognia: 17 July 2026

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene TherapyAmerican Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy · 2026Added 29 Jul 2026PodcastInfographic

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyELN-DAVID MRD Working Party · 2026Added 29 Jul 2026

An International Survey on the Assessment of Screening and Treatment of Thrombosis Complications in Pediatrics (ASTRO-Kids): communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisAmerican Society for Radiation Oncology · 2026Added 23 Jul 2026

Guidelines for the management of acute porphyria: recommendations from the International Porphyria NetworkEuropean Respiratory Society · 2026Added 23 Jul 2026

Standardization of Platelet Activation Tests for the Diagnosis of Heparin-Induced Thrombocytopenia: Communication from the ISTH-SSC Subcommittee on Immune-Mediated Platelet DisordersInternational Society on Thrombosis and Haemostasis · 2026Added 23 Jul 2026

Emergent Transfusion and Hemolytic Disease of the Fetus and Newborn Risk Mitigation in Females of Childbearing Potential with Life-Threatening Bleeding: A Clinical Practice GuidelineJournal of the American College of Surgeons · 2026Added 23 Jul 2026PDF

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel RecommendationsAmerican journal of hematology · 2026Added 18 Jul 2026PDF

LYSA 2026Large B-cell lymphoma: The LYSA pragmatic guidelinesThe LYSA · 2026Added 18 Jul 2026PDF

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025Cancers · 2026Added 18 Jul 2026PDF

ASH 2026American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsAmerican Society of Hematology · 2026Added 17 Jul 2026PDF